Damora Therapeutics, Inc. (DMRA)
21.49
-0.52
(-2.36%)
USD |
NASDAQ |
Oct 30, 16:00
21.48
0.00 (0.00%)
After-Hours: 20:00
Damora Therapeutics Enterprise Value : 916.55M for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | 916.55M |
| October 29, 2026 | 948.66M |
| October 28, 2026 | 923.96M |
| October 27, 2026 | 945.57M |
| October 26, 2026 | 902.34M |
| October 23, 2026 | 891.85M |
| October 22, 2026 | 930.13M |
| October 21, 2026 | 919.02M |
| October 20, 2026 | 865.91M |
| October 19, 2026 | 779.46M |
| October 16, 2026 | 728.20M |
| October 15, 2026 | 746.73M |
| October 14, 2026 | 727.58M |
| October 13, 2026 | 735.61M |
| October 12, 2026 | 840.28M |
| October 09, 2026 | 891.23M |
| October 08, 2026 | 859.12M |
| October 07, 2026 | 839.36M |
| October 06, 2026 | 796.75M |
| October 05, 2026 | 838.12M |
| October 02, 2026 | 864.68M |
| October 01, 2026 | 838.74M |
| September 30, 2026 | 903.58M |
| September 29, 2026 | 865.29M |
| September 28, 2026 | 870.85M |
| Date | Value |
|---|---|
| September 25, 2026 | 865.29M |
| September 24, 2026 | 841.21M |
| September 23, 2026 | 851.71M |
| September 22, 2026 | 973.36M |
| September 21, 2026 | 1.001B |
| September 18, 2026 | 984.48M |
| September 17, 2026 | 996.21M |
| September 16, 2026 | 1.104B |
| September 15, 2026 | 1.118B |
| September 14, 2026 | 1.343B |
| September 11, 2026 | 1.325B |
| September 10, 2026 | 1.247B |
| September 09, 2026 | 1.212B |
| September 08, 2026 | 1.391B |
| September 04, 2026 | 1.446B |
| September 03, 2026 | 1.319B |
| September 02, 2026 | 1.330B |
| September 01, 2026 | 1.327B |
| August 31, 2026 | 1.330B |
| August 28, 2026 | 1.380B |
| August 27, 2026 | 1.479B |
| August 26, 2026 | 1.466B |
| August 25, 2026 | 1.480B |
| August 24, 2026 | 1.461B |
| August 21, 2026 | 1.493B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.662B |
| Alnylam Pharmaceuticals, Inc. | 21.50B |
| Anika Therapeutics, Inc. | 267.21M |
| Savara, Inc. | 847.40M |
| Vericel Corp. | 1.992B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.17M |
| Total Expenses (Quarterly) | 31.17M |
| EPS Diluted (Quarterly) | -0.5099 |
| Earnings Yield | -580.7% |
| Normalized Earnings Yield | -238.11 |